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It is important to identify the mechanisms by which tumor
cells invade surrounding tissues, in hopes of being able to
develop therapies that will improve patient survival. The
degradation of the basement membrane and/or degradation
of other extracellular matrix protein barriers that may be
present in the neighboring connective tissue has been
thought to be necessary for tumor cells to invade. Drugs to
inhibit an important class of extracellular proteases, the
matrix metalloproteases (MMPs), were therefore developed,
but a major setback was the limited success of these drugs in
prolonging patient survival.
Among the various explanations proposed [1-3], a particu-
larly intriguing one was provided by Wolf and Friedl in 2003
[4]. They found that for some fibrosarcoma (HT1080) and
breast cancer (MDA-MB-231) cells, inhibition of MMP
activity did not block invasion through three-dimensional
tissue, but instead led to a conversion in cell morphology
and type of migration. Before treatment the cells typically
had an elongated, ‘mesenchymal’ morphology during
invasion, but addition of MMP inhibitors resulted in a
rounded, ‘amoeboid’ morphology - with little difference in
the rate of invasion as the amoeboid cells could squeeze
though gaps in the matrix. Mesenchymal migration is more
fibroblast-like, with elongated cells that have stress fibers
and can exert force to restructure the extracellular matrix,
whereas amoeboid migration is characterized by round/
ellipsoid cells with high cortical tension and low, but
significant, adhesion to matrix [5,6]. Mesenchymal cells
move through extension of lamellar structures that attach
and pull the cell forwards, whereas amoeboid cells tend to
produce blebbing protrusions and use cortical contraction to
squeeze the cell through spaces in the extracellular matrix
[7] (Figure 1).
In the same year, Sahai and Marshall [8] extended these
results to other tumor types, including melanoma and
squamous cell carcinoma, and began the dissection of the
signaling pathways that regulate the conversion. Amoeboid
behavior was dependent on the presence of a three-
dimensional tissue environment and was inhibited by C3
exoenzyme, a toxin that inhibits the A, B and C isoforms of
the small GTPase Rho. The Rho family of GTPases, which
also includes the Rac and Cdc42 proteins, is involved in
controlling many cellular properties, including morpho-
genesis, cell motility and the organization of the cyto-
skeleton. The activity of these small GTPases is controlled by
guanine-nucleotide exchange factors (GEFs) that promote
the active GTP-bound form and by GTPase-activating
proteins (GAPs) that favor the inactive GDP-bound form.
As RhoA, B and C are likely to perform distinct functions in
migration and invasion [7,9], it will be important to
elucidate which of these isoforms contribute to amoeboid-
type invasion. Notably, a role for RhoC in amoeboid
behavior has been proposed in an elegant study using
intravital imaging of cells in zebrafish xenografts [10], with
the caveat that overexpression may obscure isoform-specific
functions. Further evidence has indicated a role for the
serine/threonine kinase ROCK, a Rho effector that is a keyregulator of myosin contractility, probably acting by
stiffening the cell cortex [11,12]. In a paper published
recently in Cell, Sanz-Moreno et al. [13] now provide insight
into the roles of Rho and Rac and their interacting GEFs and
GAPs in the interconversion of a melanoma cell line between
mesenchymal and amoeboid modes.
There are more than 80 Rho GEFs and more than 70 Rho
GAPs in the human genome [14-16], a vast excess over the
number of different Rho-family GTPases. Although part of
this discrepancy can be accounted for by tissue-specific
expression of a number of these regulators, it is likely that a
significant fraction of them is expressed in any given cell.
The reigning hypothesis is that different GEFs mediate
specific inputs from a small subset of receptors to the
respective GTPases [17]. However, the precise connections
between receptors and GEFs remains largely uncharted. To
date, even less is known about how GAPs are regulated [16].
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To identify Rho GEFs and GAPs that control inter-
convertibility, Sanz-Moreno et al. [13] used small
interfering RNAs (siRNAs) to knockdown expression of 83
Rho GEFs in the melanoma cell line A375M2. This line
displays a predominantly amoeboid phenotype with a
minority of cells that migrate in a mesenchymal fashion.
The authors found that depletion of DOCK3, a GEF specific
for Rac, or of NEDD9, an adaptor protein of the p130Cas
family that binds DOCK3, reduced the fraction of elongated
(mesenchymal) cells. Moreover, siRNA-mediated depletion
of Rac1 itself also reduced the fraction of elongated cells,
while conversely, inhibitors of ROCK or myosin increased
the levels of GTP-bound Rac (Rac-GTP) concomitantly with
the fraction of elongated cells. Thus, these observations
indicate that Rac1 signaling is important for maintaining
the mesenchymal mode.
Sanz-Moreno et al. also identified WAVE2, a protein that
promotes actin nucleation downstream of Rac, as a critical
mediator of the elongated phenotype. Interestingly, deple-
tion of either Rac1 or WAVE2 stimulated actomyosin con-
tractility, evidenced by increased phosphorylation of the
regulatory subunit of myosin II. This indicates that Rac,
through WAVE2, could promote mesenchymal behavior in a
dual fashion - by stimulating actin polymerization and cell
protrusion and by restraining myosin contractility (Figure 2).
Precisely how WAVE2 negatively regulates contractility
remains to be defined. Activated Rac has also been shown to
stimulate the activity of p190RhoGAP (which downregulates
the activity of Rho isoforms), either by directly binding to it
and relieving autoinhibition [18] or by promoting its phos-
phorylation by tyrosine kinases [19]. This suggests there may
be additional mechanisms by which Rac can inhibit the Rho-
mediated amoeboid phenotype.
To elucidate how ROCK signaling suppresses Rac activation,
Sanz-Moreno et al. screened an siRNA library targeting 72
Rho-family GAPs. They identified one GAP, ARHGAP22,
whose silencing led to increased numbers of elongated cells
and increased the levels of Rac-GTP. If ARHGAP22 was
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Characteristics of the mesenchymal and amoeboid cell phenotypes.
Mesenchymal Amoeboid
Elongated
Lamellipodia
Strong adhesion
MMP activity
Low cortical tension
Low Rho/ROCK
activity 
Rounded
Blebbing protrusions
Weak adhesion
Low MMP
High cortical tension
High Rho/ROCK
activity 
3D
Thick/soft substratum
2D
Firm substratum
F Fi ig gu ur re e   2 2
Signaling control of mesenchymal and amoeboid cell phenotypes. The
reciprocal inhibitory relationship between Rac and Rho signaling cascades
establishes a bistable switch that controls the mesenchymal and amoeboid
phenotypes. Mesenchymal morphology is controlled by a pathway that
activates Rac1 via the adaptor protein NEDD9 and the Rac-specific GEF
DOCK3. Rac1 activation results in actin polymerization mediated by the
actin-nucleation protein WAVE2, which promotes cell elongation.
WAVE2 somehow also suppresses actomyosin contractility and,
consequently, amoeboid behavior. On the other hand, Rho/ROCK
activation stimulates actomysoin contractility, thereby promoting the
amoeboid phenotype, and inhibits Rac by activating the Rac-specific GAP,
ARHGAP22. Presumably both Rac1 and Rho activation are ultimately
controlled by integrin activity, but precisely how the extracellular
environment favors either Rac or Rho signaling remains to be resolved.
Solid arrows, direct connections; dashed arrows, indirect connections.
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contractilitydepleted, the reduction in Rac-GTP levels by ROCK activation
was blocked, indicating that ARHGAP22 did indeed mediate
a Rho/ROCK-driven negative input to Rac. Thus, increased
Rho signaling, via the Rho effector ROCK, might not only
promote amoeboid behavior directly, but also actively restrain
mesenchymal-type movement by activating ARHGAP22, in a
manner yet to be elucidated. This reciprocal inhibitory
relationship between the Rac and Rho GTPases could form a
bistable switch that reinforces selection of one mode of
migration over the other.
Metastasis is a multistep process that requires the adap-
tability of malignant cells to different microenvironments.
Sanz-Moreno et al. also employed intravital imaging of GFP-
expressing melanoma cells in subcutaneous xenografts,
powerfully illustrating this adaptability and emphasizing the
importance of examining migration mechanisms in live
animals. Whereas in the core of the tumor, melanoma cells
predominantly moved in an elongated/mesenchymal fashion,
cells at the tumor edge migrated into the matrix in a
rounded/amoeboid manner. Suppression of ARHGAP22
activity increased the proportion of elongated cells, consis-
tent with the in vitro studies indicating that this should
increase Rac activation. Treatment with the ROCK inhibitor
Y27632 also reduced amoeboid movement and increased the
number of cells moving in the mesenchymal mode within
the tumor. Intriguingly, the increased mesenchymal movement
did not occur out in the matrix, only in the tumor interior.
A confounding feature of cancer is heterogeneity among
tumors (even within a specific type such as melanoma), and
so an important question is the relevance of studies focusing
on one, or even two, lines for the disease as a whole. To
address this issue, the authors evaluated 11 melanoma cell
lines in total, and found that silencing of ARHGAP22
expression led to increased proportions of elongated cells in
most cases, whereas silencing of DOCK3 or NEDD9 reduced
the proportions of elongated cells. This evaluation of a set of
melanoma cell lines makes a strong case for the importance
of the biaxial signaling network identified in the control of
melanoma cell morphology and migration, with the caveat
that cell shape rather than motility was used as a readout.
D Dr ri iv vi in ng g   f fo or rw wa ar rd d
The study of Sanz-Moreno et al. [13] suggests a model in
which Rac activity promotes mesenchymal migration and
RhoA promotes amoeboid migration (Figure 2). Although
mutual antagonism between the Rac and Rho GTPases has
been observed in many other cellular settings [20,21], a
critical question is precisely how this antagonistic relation-
ship becomes integrated in coordinated cell behavior. One
instance is the initiation of epithelial cell-cell adhesion,
where rounds of activation and de-activation of Rac at the
contacting membrane lead to expansion of the contact zone
between cells [22]. Another example is the neuronal growth
cone, where an appropriate level of Rac activity is required
for persistent lamellar protrusion and neurite outgrowth
[23]. For melanoma, Sanz-Moreno et al. identify mutual
suppression mechanisms mediated by ARHGAP22 and
WAVE2 function that can help maintain the cell in a single
mode for effective movement. The details of how ARHGAP22
is activated and how WAVE2 leads to Rho suppression are
areas for further study.
On an operational level, these studies indicate an approach
to testing whether motility in vivo can be interpreted in
terms of mesenchymal versus amoeboid modes of invasion.
Treatment with ROCK inhibitors such as Y27632 can be
used to inhibit amoeboid motility while maintaining or
increasing the proportion of cells that are invading in the
mesenchymal mode. Conversely, inhibitors of Rac or MMPs
can be used to inhibit cells migrating in the mesenchymal
mode and possibly increase migration in the amoeboid
mode. Intravital time-lapse imaging will help distinguish
between simply morphological alterations and changes in
real invasive properties. Treatment of tumors with these or
related inhibitors provides an opportunity to evaluate in
vivo the contributions of mesenchymal and amoeboid
motility to tumor cell invasion and metastasis.
An important consequence of the plasticity of the invasive
behavior of tumor cells is that interfering with elements that
control either migration mode would allow cells to switch to a
different mode of invasion and consequently may have little
effect on the extent of cell invasion. In line with previous
observations [8], Sanz-Moreno et al. show that simultaneous
blocking of both modes of migration diminishes this
opportunistic behavior and significantly inhibits invasion.
These findings have important therapeutic implications,
indicating the potential clinical benefit of combinations of
drugs targeting the respective modes of invasion.
An intriguing question that remains to be addressed is what
are the upstream signals that lead to activation of Rac,
thereby driving mesenchymal motility or activation of RhoA
for amoeboid motility. There are three general conditions
that we know of that contribute to the selection of the
mesenchymal or amoeboid mode: MMP activity levels;
rigidity of the substratum; and level of integrin activity.
Inhibition of MMPs, reduced matrix rigidity, or reduced
levels of integrin activity result in amoeboid migration. The
challenge will be to construct a unifying model that
integrates these features (Figure 2). Only then will it be
possible to connect this intricate signaling network to the
tumor microenvironment that is driving it.
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